Dr. David Reardon is the clinical director of the Center of Neuro-oncology at the Dana-Farber Cancer Institute as well as a professor of medicine at Harvard Medical School. He is currently the study chair of the clinical trial “Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma” (NCT02336165).
Brain and nervous system cancers account for one in every one hundred cancer diagnoses in the United States, and are two of the main cancers that affect children and young adults – 21% of all pediatric cancers are brain cancer. 300,000 individuals from around the world are diagnosed with this disease every year, culminating in over 240,000 deaths. Glioblastoma is the most dangerous and aggressive form of brain cancer. Only a quarter of newly diagnosed patients survive for at least two years, and fewer than 10% of patients survive for more than five years.
This trial examines various combinations of a checkpoint immunotherapy, a targeted antibody, and radiation in patients with an aggressive form of brain cancer known as glioblastoma. The checkpoint inhibitor durvalumab (Imfinzi™) blocks the PD-L1 pathway, the antibody bevacizumab (Avastin®) targets the VEGF pathway and thus impedes tumor blood vessel growth, and radiation can both kill cancer cells and alert the immune system to the cancer’s presence.
Additional investigators working on this trial include:
- Hui Gan, M.D. (Austin Hospital, Australia)
- Thomas Kaley, M.D. (Memorial Sloan Kettering Cancer Center)
- Tim Cloughesy, M.D. (University of California, Los Angeles)
- Michael Lim, M.D. (Johns Hopkins Medicine)
- Jennifer Clarke, M.D. (University of California, Los Angeles)
- Gavin Peter Dunn, M.D., Ph.D. (Washington University, St Louis)
- Jorg Dietrich, M.D. (Mass General Hospital)
Projects and Grants
Phase 2 Study of Durvalumab (MEDI4736) in Patients With Glioblastoma (NCT02336165)
Dana-Farber Cancer Institute | Brain Cancer | 2014
Let's spread the word about Immunotherapy! Click to share this page with your community.